Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Berzosertib (VE-822) has been used in trials studying the treatment of Ovarian Neoplasms, Ovarian Serous Tumor, Adult Solid Neoplasm, Advanced Solid Tumor, and Advanced Solid Neoplasm, among others.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 33.00 | |
2 mg | In stock | $ 45.00 | |
5 mg | In stock | $ 70.00 | |
10 mg | In stock | $ 100.00 | |
25 mg | In stock | $ 228.00 | |
50 mg | In stock | $ 343.00 | |
100 mg | In stock | $ 538.00 | |
200 mg | In stock | $ 665.00 | |
500 mg | In stock | $ 1,050.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 70.00 |
Description | Berzosertib (VE-822) has been used in trials studying the treatment of Ovarian Neoplasms, Ovarian Serous Tumor, Adult Solid Neoplasm, Advanced Solid Tumor, and Advanced Solid Neoplasm, among others. |
Targets&IC50 | ATR:19 nM |
In vitro | Compared to the individual effects of XTR, the combination of 60 mg/kg VE-822 and XTR doubled the time required for tumors to reach 600 mm³ in mice carrying PSN-1 and MiaPaCa-2 tumors. This co-administration significantly prolonged tumor growth delay in PSN-1 tumor-bearing mice compared to the combination of gemcitabine and XRT1, highlighting VE-822's effectiveness. Additionally, the combination of 60 mg/kg VE-822 and XRT1 resulted in a 44% increase in tumor uptake versus XRT1 alone, demonstrating that VE-822 enhances the persistence of DNA damage caused by XRT through increased γH2AX phosphorylation. Furthermore, VE-822 inhibits the phosphorylation of serine 345-Chk1 in PSN-1 tumors in mice, indicating its potential role in cancer treatment strategies. |
In vivo | At a concentration of 80 nM, VE-822 alone increased the proportion of MiaPaCa-2 and PSN-1 cells remaining in the G1 phase and eliminated enriched G2/M phase fractions containing XRT in these cells. VE-822's sole application had limited impact, but its combination with XRT and/or gemcitabine significantly enhanced both early and late apoptosis in PSN-1 cells. VE-822 also heightened tumor response to agents causing DNA damage associated with (pChk1 Ser345) blockade. Furthermore, VE-822 (80 nM) attenuated the ATR signaling pathway, reducing tumor cell survival rates in response to XRT and gemcitabine. However, in normal cells, although 80 nM VE-822 weakened the ATR signaling pathway, it did not increase the killing ability of radiation and gemcitabine against these cells. |
Kinase Assay | A375 cells are pre-treated with 1 μM JNK-IN-8 for the indicated amounts of time. Remove the medium and wash 3 times with PBS. Resuspend the cell pellet with 1 mL Lysis Buffer (1% NP-40, 1% CHAPS, 25 mM Tris, 150 mM NaCl, Phosphatase Inhibitor Cocktail, and Protease Inhibitor Cocktail). Rotate end-to-end for 30 min at 4°C. Lysates are cleared by centrifugation at 14000 rpm for 15 min in the Eppendorf. The cleared lysates gel filtered into Kinase Buffer (0.1% NP-40, 20 mM HEPES, 150 mM NaCl, Phosphatase Inhibitor Cocktail, Protease Inhibitor Cocktail) using Bio-Rad 10DG colums. The total protein concentration of the gel-filtered lysate should be around 5-15 mg/mL. Cell lysate is labeled with the probe from ActivX at 5 μM for 1 hour. Samples are reduced with DTT, and cysteines are blocked with iodoacetamide and gel filtered to remove excess reagents and exchange the buffer. Add 1 volume of 2X Binding Buffer (2% Triton-100, 1% NP-40, 2 mM EDTA, 2X PBS) and 50 μL streptavidin bead slurry and rotate end-to-end for 2 hours, centrifuge at 7000 rpm for 2 min. Wash 3 times with 1X Binding Buffer and 3 times with PBS. Add 30 μL 1X sample buffer to beads, heat samples at 95°C for 10 min. Run samples on an SDS-PAGE gel at 110V. After transferred, the membrane is immunoblotted with JNK antibody[1]. |
Cell Research | VE-822 is dissolved in DMSO and stored, and then diluted with appropriate media before use[1]. Gemcitabine (10 nM) is added 24 h pre-XRT and is replaced with fresh medium before addition of VE-822. PSN-1 cells are treated with VE-822 (80 nM) for 1 h before, through to 18 h after, XRT (6 Gy). Apoptosis is analyzed 48 h after XRT by flow cytometry using an Annexin V-FITC kit with PI[1]. |
Synonyms | VX-970, VE-822 |
Molecular Weight | 463.55 |
Formula | C24H25N5O3S |
CAS No. | 1232416-25-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 34 mg/mL (73.3 mM)
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Berzosertib 1232416-25-9 DNA Damage/DNA Repair PI3K/Akt/mTOR signaling ATM/ATR VE 822 VX 970 VX-970 VX970 VE822 VE-822 inhibitor inhibit